Table 2.
Details of vaccination histories of study participants recovered from SARS-CoV-2 BA.5 infection, Chengdu China, December 2022– January 2023 (n = 108)
| Volunteer | Sex | Age | The first dose | The second dose | The third dose | Group |
|---|---|---|---|---|---|---|
| 1 | Male | 34 | / | / | / | Unvaccinated group (n = 22): 22 adult participants have not received injection of vaccine with infection |
| 2 | Female | 30 | / | / | / | |
| 3 | Female | 30 | / | / | / | |
| 4 | Female | 25 | / | / | / | |
| 5 | Female | 32 | / | / | / | |
| 6 | Male | 30 | / | / | / | |
| 7 | Female | 31 | / | / | / | |
| 8 | Female | 28 | / | / | / | |
| 9 | Female | 31 | / | / | / | |
| 10 | Female | 33 | / | / | / | |
| 11 | Female | 32 | / | / | / | |
| 12 | Male | 29 | / | / | / | |
| 13 | Male | 24 | / | / | / | |
| 14 | Female | 27 | / | / | / | |
| 15 | Male | 24 | / | / | / | |
| 16 | Female | 31 | / | / | / | |
| 17 | Male | 31 | / | / | / | |
| 18 | Male | 33 | / | / | / | |
| 19 | Female | 35 | / | / | / | |
| 20 | Female | 37 | / | / | / | |
| 21 | Male | 35 | / | / | / | |
| 22 | Female | 41 | / | / | / | |
| 23 | Male | 27 | CoronaVac | CoronaVac | / | 2 doses of IV group (n = 25): adult participants who have received two doses of inactivated vaccines with infection |
| 24 | Female | 28 | CoronaVac | CoronaVac | / | |
| 25 | Male | 25 | CoronaVac | CoronaVac | / | |
| 26 | Female | 24 | CoronaVac | CoronaVac | / | |
| 27 | Male | 31 | CoronaVac | CoronaVac | / | |
| 28 | Male | 21 | BBIBP | BBIBP | / | |
| 29 | Female | 25 | CoronaVac | CoronaVac | / | |
| 30 | Female | 25 | BBIBP | BBIBP | / | |
| 31 | Male | 25 | CoronaVac | CoronaVac | / | |
| 32 | Female | 25 | BBIBP | BBIBP | / | |
| 33 | Female | 31 | CoronaVac | CoronaVac | / | |
| 34 | Male | 24 | CoronaVac | CoronaVac | / | |
| 35 | Male | 27 | CoronaVac | CoronaVac | / | |
| 36 | Female | 24 | CoronaVac | CoronaVac | / | |
| 37 | Male | 31 | CoronaVac | BBIBP | / | |
| 38 | Male | 31 | BBIBP | BBIBP | / | |
| 39 | Female | 33 | BBIBP | BBIBP | / | |
| 40 | Male | 35 | CoronaVac | BBIBP | / | |
| 41 | Female | 37 | CoronaVac | BBIBP | / | |
| 42 | Male | 35 | CoronaVac | CoronaVac | / | |
| 43 | Male | 41 | CoronaVac | CoronaVac | / | |
| 44 | Female | 43 | CoronaVac | CoronaVac | / | |
| 45 | Female | 31 | CoronaVac | CoronaVac | / | |
| 46 | Male | 47 | CoronaVac | CoronaVac | / | |
| 47 | Female | 49 | CoronaVac | CoronaVac | / | |
| 48 | Female | 23 | CoronaVac | CoronaVac | CoronaVac | 3 doses of IV group (n = 39): adult participants who have received three doses of inactivated vaccines with infection |
| 49 | Female | 22 | CoronaVac | CoronaVac | CoronaVac | |
| 50 | Male | 29 | CoronaVac | CoronaVac | CoronaVac | |
| 51 | Female | 23 | CoronaVac | CoronaVac | CoronaVac | |
| 52 | Male | 25 | CoronaVac | CoronaVac | CoronaVac | |
| 53 | Male | 29 | BBIBP | BBIBP | BBIBP | |
| 54 | Female | 52 | CoronaVac | CoronaVac | CoronaVac | |
| 55 | Female | 29 | BBIBP | BBIBP | BBIBP | |
| 56 | Female | 28 | CoronaVac | CoronaVac | CoronaVac | |
| 57 | Female | 25 | CoronaVac | CoronaVac | CoronaVac | |
| 58 | Female | 24 | CoronaVac | CoronaVac | CoronaVac | |
| 59 | Female | 24 | CoronaVac | BBIBP | BBIBP | |
| 60 | Female | 24 | CoronaVac | BBIBP | BBIBP | |
| 61 | Female | 23 | CoronaVac | CoronaVac | CoronaVac | |
| 62 | Female | 35 | CoronaVac | CoronaVac | CoronaVac | |
| 63 | Female | 30 | CoronaVac | CoronaVac | BBIBP | |
| 64 | Female | 23 | CoronaVac | CoronaVac | CoronaVac | |
| 65 | Male | 28 | CoronaVac | BBIBP | BBIBP | |
| 66 | Female | 31 | CoronaVac | CoronaVac | CoronaVac | |
| 67 | Female | 28 | CoronaVac | CoronaVac | CoronaVac | |
| 68 | Female | 41 | CoronaVac | CoronaVac | CoronaVac | |
| 69 | Female | 27 | CoronaVac | CoronaVac | CoronaVac | |
| 70 | Male | 35 | CoronaVac | CoronaVac | CoronaVac | |
| 71 | Male | 42 | CoronaVac | CoronaVac | CoronaVac | |
| 72 | Female | 25 | CoronaVac | CoronaVac | CoronaVac | |
| 73 | Female | 41 | CoronaVac | CoronaVac | CoronaVac | |
| 74 | Female | 27 | CoronaVac | CoronaVac | CoronaVac | |
| 75 | Female | 36 | CoronaVac | CoronaVac | CoronaVac | |
| 76 | Male | 39 | BBIBP | BBIBP | BBIBP | |
| 77 | Male | 28 | CoronaVac | CoronaVac | CoronaVac | |
| 78 | Female | 31 | CoronaVac | CoronaVac | CoronaVac | |
| 79 | Male | 28 | CoronaVac | CoronaVac | CoronaVac | |
| 80 | Female | 41 | BBIBP | BBIBP | BBIBP | |
| 81 | Male | 27 | BBIBP | BBIBP | BBIBP | |
| 82 | Male | 35 | CoronaVac | BBIBP | BBIBP | |
| 83 | Female | 42 | CoronaVac | BBIBP | BBIBP | |
| 84 | Female | 25 | CoronaVac | BBIBP | BBIBP | |
| 85 | Male | 41 | BBIBP | BBIBP | BBIBP | |
| 86 | Female | 27 | CoronaVac | CoronaVac | CoronaVac | |
| 87 | Male | 73 | BBIBP | BBIBP | BBIBP | Elderly group (n = 22): elderly participants who were over 65 years with infection |
| 88 | Female | 71 | CoronaVac | CoronaVac | CoronaVac | |
| 89 | Male | 66 | CoronaVac | CoronaVac | CoronaVac | |
| 90 | Male | 66 | CoronaVac | CoronaVac | CoronaVac | |
| 91 | Male | 69 | CoronaVac | CoronaVac | CoronaVac | |
| 92 | Male | 79 | CoronaVac | CoronaVac | CoronaVac | |
| 93 | Male | 83 | CoronaVac | CoronaVac | CoronaVac | |
| 94 | Female | 69 | CoronaVac | CoronaVac | CoronaVac | |
| 95 | Female | 73 | CoronaVac | CoronaVac | CoronaVac | |
| 96 | Male | 71 | CoronaVac | CoronaVac | CoronaVac | |
| 97 | Male | 72 | CoronaVac | CoronaVac | CoronaVac | |
| 98 | Female | 70 | CoronaVac | CoronaVac | CoronaVac | |
| 99 | Male | 73 | CoronaVac | CoronaVac | CoronaVac | |
| 100 | Female | 71 | CoronaVac | CoronaVac | CoronaVac | |
| 101 | Male | 66 | CoronaVac | CoronaVac | CoronaVac | |
| 102 | Female | 66 | CoronaVac | CoronaVac | CoronaVac | |
| 103 | Male | 69 | CoronaVac | CoronaVac | CoronaVac | |
| 104 | Male | 79 | CoronaVac | CoronaVac | CoronaVac | |
| 105 | Female | 83 | CoronaVac | CoronaVac | CoronaVac | |
| 106 | Female | 69 | CoronaVac | CoronaVac | CoronaVac | |
| 107 | Male | 73 | CoronaVac | CoronaVac | CoronaVac | |
| 108 | Female | 71 | CoronaVac | CoronaVac | CoronaVac |
CoronaVac: inactivated vaccines from Sinovac Life Sciences Co., Ltd
BBIBP: inactivated vaccines from Beijing Institute of Biological Products Co., Ltd